Bicara Therapeutics Inc. (BCAX) vs Puma Biotechnology, Inc. (PBYI)

Bicara Therapeutics Inc. and Puma Biotechnology, Inc. are both Biotechnology companies. Bicara Therapeutics Inc. is the larger, with a market value of $592.9M against $527.6M — 1.1× the size. Bicara Therapeutics Inc. has negative trailing earnings, so its P/E is not meaningful; Puma Biotechnology, Inc. trades at 18.9×. Puma Biotechnology, Inc. has the higher net margin (11.6% vs 0.00%) and the higher return on invested capital (42.6% vs 0.00%). Across the 12 metrics below, Puma Biotechnology, Inc. leads on 9 and Bicara Therapeutics Inc. on 3.

Valuation

Metric BCAX PBYI Biotechnology median
P/E n/m 18.94 10.64
P/S n/m 2.25 9.59
P/B 1.29 3.76 2.15
Price to free cash flow n/m 18.24 26.07
EV/EBITDA n/m 10.98 0.65
EV/Sales n/m 1.94 9.45
Earnings yield (34.71%) 5.28% (34.69%)
Free cash flow yield (22.30%) 5.48% (24.02%)

Profitability

Metric BCAX PBYI Biotechnology median
Gross margin — 74.83% 65.59%
Operating margin 0.00% 13.16% 0.00%
Net margin 0.00% 11.55% 0.00%
Free cash flow margin 0.00% 17.79% 0.00%
Return on equity (41.01%) 21.97% (51.96%)
Return on assets (38.38%) 13.78% (46.06%)
Return on invested capital 0.00% 42.61% 0.00%

Growth

Metric BCAX PBYI Biotechnology median
Revenue growth (TTM) — (2.86%) 4.59%
EPS growth (last fiscal year) 37.78% (1.61%) 29.88%
Revenue growth, 5-year CAGR — 0.29% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric BCAX PBYI Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.59 2.91 4.86
Net debt to EBITDA 2.67 (1.60) 1.01

Dividend

Metric BCAX PBYI Biotechnology median
Dividend yield — — 0.38%
Payout ratio — — —

Size

Metric BCAX PBYI Biotechnology median
Market cap 592.91m 527.55m 174.29m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack